Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC

This is a randomized, open-label, multi-center Phase III clinical study aimed at head-to-head evaluating the clinical efficacy of three immunotherapy strategies, namely perioperative immunotherapy, neoadjuvant immunotherapy, and adjuvant immunotherapy using Toripalimab, in patients with resectable stage II-IIIA non-small cell lung cancer (NSCLC) without EGFR/ALK sensitive mutations. This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1030.

Trial Details

NCT ID

NCT07554846

Phase

PHASE3

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Peroperative immunotherapy
Neoadjuvant immunotherapy
Adjuvant immunotherapy

Locations (sample)

Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

Aged 18-75, of either gender;
Subjects with resectable stage II-IIIA non-small cell lung cancer (according to the AJCC 8th edition), without EGFR/ALK sensitive mutations, confir…
ECOG PS score of 0-1;
There are measurable lesions according to RECIST 1.1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →